Detalhes bibliográficos
| Ano de defesa: |
2015 |
| Autor(a) principal: |
Acioli, Gláucia da Rocha
 |
| Orientador(a): |
Oliveira Júnior, Antonio Martins de
|
| Banca de defesa: |
Não Informado pela instituição |
| Tipo de documento: |
Dissertação
|
| Tipo de acesso: |
Acesso aberto |
| Idioma: |
por |
| Instituição de defesa: |
Universidade Federal de Sergipe
|
| Programa de Pós-Graduação: |
Pós-Graduação em Ciência da Propriedade Intelectual
|
| Departamento: |
Não Informado pela instituição
|
| País: |
BR
|
| Palavras-chave em Português: |
|
| Palavras-chave em Inglês: |
|
| Área do conhecimento CNPq: |
|
| Link de acesso: |
https://ri.ufs.br/handle/riufs/3403
|
Resumo: |
Technological innovation is an important instrument of competitiveness in the face of new market requirements for sustainable enterprises. In this sense, it can be used strategically not only the advantage to reduce competition from the differentiation of a new product, but also to position domain dialing in profitable and competitive markets. Therefore, it is essential to protect the new assets in various industrial sectors. Among the hedging instruments relating to intellectual property rights are patents, which provide many competitive advantages to its owner, not allowing others to use, distribute, import or sell without his consent. In the pharmaceutical sector, where the products produced to solve many health problems of the population result from expensive processes, patents become an incentive for innovation. Considering the economic and social importance of patenting activity and the pharmaceutical industry for the country, this paper conducted a systematic analysis of patenting the Brazilian pharmaceutical industry, evaluating patent applications filed at INPI basis by industry-leading companies and analyzing indicators for categorization of trends and strategies. The results mainly showed the recent growth of the domestic pharmaceutical industry, as cycle of technological life, the analytical strategic behavior of EMS and Eurofarma companies, the defender, Chemical Union, and the prospector, the Aché and Hypermarcas and market opportunities for investments of Brazilian pharmaceutical companies in oncology areas and allergic. |
